FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)
16.0 pt (24h)GeopoliticaOne-OffHealth & Medicine3m
KalshiVerifica disponibilitàKYC richiesto2% di commissioneDati di risoluzione verificatiDiscretamente calibratoProbabilità implicita attuale
Sì 98%+16.0pt
Qualità del mercato
44 / 100
Bassa qualitàVolume 24h
510,9 €
Liquidità
156,6 €
Bassa liquiditàBid / Ask
80.0% / 88.0%
Spread
8.0 pt
Spread ampioDati di mercato
Aggiornato 10 minuti fa
17 giu 26, 21:00 UTC1 gen 27, 04:59 UTC
Trend
Mercati Correlati
Domande correlate per il contesto, non un confronto tra contratti equivalenti.
FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)
KalshiFDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
KalshiFDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026)
KalshiDid COVID-19 come from a laboratory?
Manifold MarketsWhich states will report local cases in the May 2026 Ebola Bundibugyo outbreak
Manifold MarketsWhen, where or how will Trump die?
Manifold MarketsRegole
If the FDA's decision on Ifinatamab Deruxtecan by Daiichi Sankyo in 2026 is a full approval or an accelerated approval, the market resolves to Yes.
Si regola tramite:AppliedXL
- This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
- Ifinatamab deruxtecan (also called I-DXd or DS-7300) is an antibody-drug conjugate — think of it as a guided missile where a targeting protein is chemically linked to a potent cancer-killing payload.
- The targeting protein homes in on a molecule called B7-H3 (also known as CD276), which appears in unusually high amounts on the surface of many cancer cells, and once the drug locks onto that target it is pulled inside the cell and releases its toxic payload.
- In doing so, it aims to kill tumor cells more precisely than traditional chemotherapy, which attacks both healthy and cancerous cells indiscriminately.
Mercati aperti
Geopolitics
POLYMARKETWhich party will gain most seats in Russian Parliamentary Election?
- United Russia (ER)+5.0pt75%
- New People (NL)-4.1pt21%
- Liberal Democratic Party of Russia (LDPR)-1.1pt3%
+5 altri esiti
- Volume totale
- 22,2 Mln €
- Volume 24h
- 470,8K €
POLYMARKETUS announces end of Iranian blockade by which date?
- December 31-2.3pt48.3%
- October 31-2.0pt29.3%
- September 30-4.0pt12.1%
+17 altri esiti
POLYMARKETUS x Iran Effective Ceasefire begins by...? (2 week pause)
- September 30+1.0pt80%
- September 18+1.0pt75%
- September 11+6.5pt70%
+2 altri esiti
POLYMARKETWill China invade Taiwan by end of 2026?
- No-0.2pt96%
- Yes+0.2pt4%
- Volume totale
- 35,3 Mln €
- Volume 24h
- 100,1K €
POLYMARKETIsrael x Iran ceasefire continues through which date?
- July 18+0.3pt100%
- July 20+0.1pt100%
- July 22+0.5pt100%
+20 altri esiti
POLYMARKETKharg Island no longer under Iranian control by which date?
- December 317%
- September 30+0.1pt1%
- July 310%
+7 altri esiti
- Volume totale
- Nobel Peace Prize Winner 2026
- US-Iran nuclear deal?
- Russia x Ukraine peace talks by which date?
- Strait of Hormuz traffic returns to normal by December 31?
- Will the U.S. invade Iran before 2027?
- Bab el-Mandeb Strait effectively closed by which date?
- What will Trump say during RNC Convention (Night 2)?
- Russia x Ukraine ceasefire agreement by which date?
- Iran-Oman Hormuz Management Agreement by which date?
- Will the Iranian regime fall by September 30?
Domande frequenti
- Quali sono le probabilità attuali per FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)?
- Kalshi quota Yes al 98% al 8 settembre 2026.
- Quando si risolve FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)?
- FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026) dovrebbe risolversi il 1 gennaio 2027.
- Come viene liquidato FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)?
- Kalshi liquida questo mercato come segue: If the FDA's decision on Ifinatamab Deruxtecan by Daiichi Sankyo in 2026 is a full approval or an accelerated approval, the market resolves to Yes.